Kathryn DiMarco - Feb 9, 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role
Corporate Controller
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kathryn DiMarco
Stock symbol
OGN
Transactions as of
Feb 9, 2022
Transactions value $
-$25,144
Form type
4
Date filed
2/10/2022, 08:10 PM
Previous filing
Aug 19, 2021
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +1.87K +232.75% $0.00 2.67K Feb 9, 2022 Direct F1
transaction OGN Common Stock Tax liability -$25.1K -745 -27.88% $33.75 1.93K Feb 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Options Exercise $0 -1.87K -33.32% $0.00 3.74K Feb 9, 2022 Common Stock 1.87K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.
F2 On June 2, 2021 in connection with the separation of Organon from Merck & Co., Inc., the restricted stock unit award was converted into a restricted stock unit award with 5,609 shares of Organon common stock underlying such award. These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments. The first installment vested and has been distributed on February 9, 2022. The remaining installments will vest and be distributed on each of February 9, 2023 and February 9, 2024.